



Oregon Prescription Drug Affordability Board

350 Winter Street NE, Salem, OR 97309-0405 | 971-374-3724 | pdab@dcbs.oregon.gov | dfr.oregon.gov/pdab

Agenda

This is a regular meeting. **Date: June 18, 2025** | **Time: 9 a.m.**

This is a draft agenda and subject to change.

Meeting name	Prescription Drug Affordability Board	Board Members: Chair Shelley Bailey; Vice Chair Amy Burns; Daniel Hartung; Robert Judge; Christopher Laman; John Murray; Dan Kennedy; Lauri Hoagland. Staff: Ralph Magrish, executive director; Cortnee Whitlock, senior policy analyst; Stephen Kooyman, project manager, Heather Doyle, data analyst; Pei-Chen Choo, research analyst; Melissa Stiles, administrative specialist; Pramela Reddi, counsel
Meeting location	Virtual	
Zoom link	Register for meeting	

Purpose	Subject	Presenter	Estimated Time Allotted
<i>Informational and vote</i>	Call to order and roll call	Chair Shelley Bailey	2 minutes
<i>Informational</i>	Board declarations of conflict of interest and meetings with entities or individuals related to board activities	Chair Shelley Bailey	2 minutes
<i>Discussion and vote</i>	Board approval of 5/21/2025 minutes	Chair Shelley Bailey	2 minutes
<i>Informational</i>	Executive director's program update	Ralph Magrish	5 minutes
<i>Informational</i>	Legislative update	Jesse O'Brien	10 minutes
<i>Informational</i>	General public comment: limited to 3 minutes	Chair Shelley Bailey	10 minutes
Discussion and vote	Board review and possible vote for updated data subset list of prescription drugs and insulin products pursuant to OAR 925-200-0010	PDAB Staff	120 minutes
Break	The board will take a break around 10:30 a.m.	Chair Shelley Bailey	5 minutes
<i>Informational</i>	Announcements	Chair Shelley Bailey	2 minutes
<i>Vote</i>	Adjournment	Chair Shelley Bailey	2 minutes

Next meeting

July 16, 2025, at 9 a.m.

Accessibility

Anyone needing assistance due to a disability or language barrier can contact Melissa Stiles at least 48 hours ahead of the meeting at pdab@dcbs.oregon.gov or 971-374-3724. American sign language will be available during the June 18 board meeting.

How to provide testimony to the board

The Prescription Drug Affordability Board invites people to provide testimony. **Oral:** To speak to the board during the public comment portion of the agenda, please submit the [PDAB public comment form](#) no later than 24 hours before the PDAB meeting. **Written:** to provide written comments to the board, please submit the [PDAB public comment form](#) with attachments no later than 48 hours before the PDAB meeting. The board reviews all written comments. All written comments are posted on the website.

Open and closed sessions

All board meetings except executive sessions are open to the public. Pursuant to ORS 192.660, executive sessions are closed to everyone but news media and staff. No action will be taken in the executive session.



Oregon Prescription Drug Affordability Board (PDAB) Regular Meeting
Wednesday, May 21, 2025
Draft Minutes

Web link to the meeting video: <https://youtu.be/Nt6vmEmieZY>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20250521-PDAB-document-package.pdf>

Call to order and roll call: Chair Shelley Bailey called the meeting to order at 9:03 a.m. and roll was called.

Board members present: Chair Shelley Bailey, Vice Chair Amy Burns, Dan Hartung, Lauri Hoagland, Dan Kennedy, John Murray

Absent: Robert Judge

The board provided Spanish interpretation and American Sign Language during the meeting.

Declaration of conflict of interest and meetings with entities or individuals related to board activities: John Murray provided a statement. View at video minute [00:01:18](#).

Approval of board minutes: Chair Bailey asked for a motion and second to approve the board minutes as shown on [Pages 5-7](#) of the agenda materials. John Murray made a motion to approve the minutes and Dan Kennedy provided a second. View at video minute [00:04:15](#).

MOTION to approve the April 16, 2025, minutes

Board Vote:

Yes: Dan Hartung, Lauri Hoagland, Dan Kennedy, John Murray, Vice Chair Amy Burns, Chair Shelley Bailey

No: None

Absent: Robert Judge

Abstain: Chris Laman

Motion passed 6-0

Executive director's program update: Ralph Magrish, executive director, Oregon Prescription Drug Affordability Board & Drug Price Transparency Program, provided a program update. View the video at minute [00:05:13](#).

Legislative update: Jesse O'Brien, Division of Financial Regulation (DFR) policy manager, provided an update on prescription drug-related bills proposed in the Oregon Legislative session as shown on [Pages 8-9](#) of the agenda materials. View the video at minute [00:10:18](#).

General Public comment: Chair Bailey called on the people who signed up in advance to speak to the board: Tiffany Westrich-Robertson, AiArthritis & EACH & PIC Coalition; Brian Mayo,



Oregon State Pharmacy Association; Bil Schmittknecht, Patient Protector; Derek Flowers, Value of Care Coalition; and Dharia McGrew, PhRMA. The board received seven written comments, which are posted on the [PDAB website](#). View the speakers at video minute [00:15:00](#).

Board discussion on timeline, process, and voting methodology for affordability

review determinations: The board reviewed the roadmap, methodology and time frame for affordability reviews, which are included in the agenda materials on [Pages 10-16](#). View the discussion at video minute [00:32:37](#).

Board review and vote on final generic drug report: Cortnee Whitlock, senior policy analyst, led the board in a discussion about the generic drug final report. The board voted to approve the report. View the final report on [Pages 17-40](#) of the agenda materials. View at video minute [01:06:24](#).

MOTION to approve the final generic drug report to send to the Oregon Legislature as discussed by the board today.

Motion made by John Murray with a second by Amy Burns.

Board vote:

Yes: Dan Hartung, Lauri Hoagland, Dan Kennedy, Chris Laman, John Murray, Vice Chair Amy Burns, Chair Shelley Bailey

No: None

Absent for the vote: Robert Judge

Motion passed 7-0

Public comment period for the list of prescription drugs and insulin products

selected for affordability review per ORS 646A.694: View the public comment at video minute [01:15:56](#).

Chair Shelley Bailey called on people who signed up in advance to speak:

Name of speaker	Association to drug under review	Drug
Lindsay Silva	Mother/primary care giver to someone living with Cystic Fibrosis	Creon
Zach Lynkiewicz,	HIV+Hepatitis Policy Institute	Odefsey
Lucy Thornehaven	National Psoriasis Foundation	Humira
Mary Jo Strobel	American Partnership for Eosinophilic Disorders	Dupixent
Ranier Simons	Community Access National Network	Odefsey
Silas Martin	Johnson and Johnson Medicines	Tremfya and Xarelto



The chair read the list of 25 submitted letters the board received. The letters are posted to the [PDAB website](#).

Name	Association to drug under review	Drug
Andrea Todd-Harlin	Sanofi	Dupixent
Gaby Gardiner	Basic Rights Oregon	Odefsey
Anne Murray	Bristol Myers Squibb	Eliquis
Kathleen Costello	Multiple Sclerosis Coalition	Ocrevus
Jane Leo	American Cancer Society, Cancer Action Network	Ibrance, Verzenio, and Perjeta
Kristie Banks	Gilead	Odefsey
Michael Valenta	Johnson & Johnson	Tremfya and Xarelto
Tim Layton	Genentech	Perjeta
Tim Layton	Genentech	Ocrevus
Seth Greiner	National Multiple Sclerosis Society	Ocrevus
Christian Omar Cruz	GSK	Trelegy
Stacie Phan	Boehringer Ingelheim	Jardiance
Cynthia Ransom	Eli Lilly	Emgality, Mounjaro, Taltz, Trulicity, Verzenio, Basaglar
Courtney Piron	Novartis	Cosentyx and Entresto
Albert Faro et al	Cystic Fibrosis Foundation	Creon
Dr. David Bernard Page	Providence Cancer Institute	Perjeta
Isabel Sheridan	Patient	Ibrance
Suzanna Masartis	Community Liver Alliance	Ozempic, Mounjaro, Rybelsus, Trulicity, Humira, Rinvoq
Linda Nelson	Oregon Coalition for Affordability Prescriptions	Trelegy
Mary Wachter	Genentech	Ocrevus, Perjeta
Ranier Simons	Community Access National Network	Odefsey
Scott Bertani	HealthHIV	Odefsey
Mary Jo Strobel,	American Partnership for Eosinophilic Disorders	Dupixent
Molly Guthrie	Susan G. Komen	Ibrance, Verzenio, Perjeta
Sarah Hoffman	Partnership to Advance Cardiovascular Health	Eliquis, Xarelto, Entresto

Announcements: Chair Bailey announced the next meeting will be June 18, 2025, at 9 a.m.

Adjournment: Chair Bailey adjourned the meeting at 11:30 a.m. with all board members in agreement. View at minute [02:04:17](#).

Bill Number	Relating To	Bill Summary	Status
HB 2057	Relating to prescription drugs; prescribing an effective date.	Prohibits insurers offering policies or certificates of health insurance and pharmacy benefit managers from requiring that a claim for reimbursement of a prescription drug include a modifier or other indicator that the drug is a 340B drug.	Passed committee April 1, still not scheduled for floor vote
HB 2149	Relating to pharmacy services administrative organization licensing.	Requires pharmacy services administrative organizations operating in this state to be licensed by the Department of Consumer and Business Services and creates rules for licensing requirements.	Referred to House Rules
HB 2385	Relating to restrictions on 340B covered entities; prescribing an effective date.	Makes it an unlawful practice for drug manufacturers to interfere directly or indirectly with a pharmacy or drug outlet acquiring 340B drugs, delivering 340B drugs to certain health care providers or dispensing 340B drugs.	Passed; signed by Governor June 11
HB 3212	Relating to pharmacy benefits.	Creates additional rules and requirements for pharmacy benefit managers and a policy or certificate of health insurance or other contract providing for the reimbursement of the cost of a prescription drug.	Referred to House Rules
HB 3226	Relating to organizations that provide services related to obtaining prescription drugs; prescribing an effective date.	Includes pharmacy services administrative organizations within the definition of pharmacies for the purpose of ensuring that pharmacy benefit managers are subject to laws regulating their activities even if their contracts are with pharmacy services administrative organizations.	Passed; signed by Governor June 11

SB 289	Relating to prescription drugs.	Introduced bill: Requires the State Board of Pharmacy to study prescription drugs. -1 amendment: Technical adjustments to laws governing PDAB including selection of drugs for affordability reviews and generic drug reporting.	Passed; Governor signed May 27
SB 533	Relating to restrictions on 340B covered entities.	Creates a civil penalty for drug manufacturers that interfere directly or indirectly with certain entities acquiring 340B drugs, delivering 340B drugs to certain health care providers or dispensing 340B drugs.	Passed committee April 3, still not scheduled for floor vote



Drugs to be removed from subset list due to FDA orphan designation

Therapy class	Propriety name(s)	Non-proprietary name	Has orphan designation	Orphan date designation
Neuromuscular agent	Botox	Onabotulinumtoxin A/ Botulinum Toxin	Yes	03/22/1984 08/20/1986 12/06/1991
Dermatologicals	Dupixent	Dupilumab	Yes	09/05/2017 08/21/2019
Analgesics– Anti-inflammatory	Humira	Humira/Humira Pen/ Humira (CF) Pen/Adalimumab	Yes	03/21/2005 10/19/2006 05/11/2011 05/13/2014 05/13/2015
Analgesics– Anti-inflammatory	Rinvoq	Upadacitinib	Yes	09/18/2015 09/20/2024



Botox

Generic Name: Botulinum toxin type A
Trade Name: Botox
Date Designated: 03/22/1984
Orphan Designation: Treatment of strabismus and blepharospasms
Orphan Designation Status: Designated/Approved

Allergan, Inc.
2525 Dupont Drive
P.O. Box 19534
Irvine, California 92713
United States

Sponsor:

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 **Generic Name:** Botulinum toxin type A
Trade Name: Botox
Marketing Approval Date: 12/29/1989
Approved Labeled Indication: Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above)
Exclusivity End Date: 12/29/1996
Exclusivity Protected Indication* :

2 **Generic Name:** Botulinum toxin type A
Trade Name: Botox
Marketing Approval Date: 12/30/1989
Approved Labeled Indication: Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above)
Exclusivity End Date: 12/30/1996
Exclusivity Protected Indication* :

Generic Name: botulinum toxin type A
Trade Name: Botox
Date Designated: 12/06/1991
Orphan Designation: Treatment of dynamic muscle contracture in pediatric cerebral palsy patients
Orphan Designation Status: Designated/Approved
Allergan, Inc.
2525 Dupont Drive
T1-2A
Sponsor: Irvine, California 92623
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 **Generic Name:** botulinum toxin type A
Trade Name: Botox
Marketing Approval Date: 06/20/2019
Approved Labeled Indication: BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.
Exclusivity End Date: 06/20/2026
Exclusivity Protected Indication* : For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age



Botox continued

Generic Name: Botulinum toxin type A
Trade Name: Botox
Date Designated: 03/22/1984
Orphan Designation: Treatment of strabismus and blepharospasms
Orphan Designation Status: Designated/Approved

Sponsor: Allergan, Inc.
2525 Dupont Drive
P.O. Box 19534
Irvine, California 92713
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 **Generic Name:** Botulinum toxin type A
Trade Name: Botox
Marketing Approval Date: 12/29/1989
Approved Labeled Indication: Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above)
Exclusivity End Date: 12/29/1996
Exclusivity Protected Indication* :

2 **Generic Name:** Botulinum toxin type A
Trade Name: Botox
Marketing Approval Date: 12/30/1989
Approved Labeled Indication: Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above)
Exclusivity End Date: 12/30/1996
Exclusivity Protected Indication* :

Generic Name: botulinum toxin type A
Trade Name: Botox
Date Designated: 12/06/1991
Orphan Designation: Treatment of dynamic muscle contracture in pediatric cerebral palsy patients
Orphan Designation Status: Designated/Approved
Sponsor: Allergan, Inc.
2525 Dupont Drive
T1-2A
Irvine, California 92623
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 **Generic Name:** botulinum toxin type A
Trade Name: Botox
Marketing Approval Date: 06/20/2019
Approved Labeled Indication: BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.
Exclusivity End Date: 06/20/2026
Exclusivity Protected Indication* : For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age



Dupixent

Generic Name: dupilumab
Trade Name: Dupixent
Date Designated: 09/05/2017
Orphan Designation: Treatment of eosinophilic esophagitis
Orphan Designation Status: Designated/Approved
Sponsor: Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

- 1** **Generic Name:** dupilumab
Trade Name: Dupixent
Marketing Approval Date: 05/20/2022
Approved Labeled Indication: Treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE)
Exclusivity End Date: 05/20/2029
Exclusivity Protected Indication* : Treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE)
- 2** **Generic Name:** dupilumab
Trade Name: Dupixent
Marketing Approval Date: 01/25/2024
Approved Labeled Indication: treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE)
Exclusivity End Date: 01/25/2031
Exclusivity Protected Indication* : treatment of pediatric patients aged 1 year and older weighing at least 15 kg who are less than 12 years of age or less than 40 kg in weight with eosinophilic esophagitis (EoE)

Generic Name: dupilumab
Date Designated: 08/21/2019
Orphan Designation: Treatment of bullous pemphigoid
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Sponsor: Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
United States

The sponsor address listed is the last reported by the sponsor to OOPD.



Humira

Generic Name: adalimumab
Trade Name: Humira
Date Designated: 03/21/2005
Orphan Designation: Treatment of juvenile rheumatoid arthritis
Orphan Designation Status: Designated/Approved
AbbVie Inc.
1 North Waukegan Road
Bldg. AP-30
North Chicago, Illinois 60064
United States

Sponsor:

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

- 1 **Generic Name:** adalimumab
Trade Name: Humira
Marketing Approval Date: 02/21/2008
Approved Labeled Indication: Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.
Exclusivity End Date: 02/21/2015
Exclusivity Protected Indication* :
- 2 **Generic Name:** adalimumab
Trade Name: Humira
Marketing Approval Date: 09/30/2014
Approved Labeled Indication: Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Exclusivity End Date: 09/30/2021
Exclusivity Protected Indication* : Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.

Generic Name: adalimumab
Trade Name: HUMIRA
Date Designated: 10/19/2006
Orphan Designation: Treatment of pediatric Crohn's disease
Orphan Designation Status: Designated/Approved
AbbVie, Inc.
1 N. Waukegan Road
Bldg AP30, Dept. PA77
North Chicago, Illinois 60064
United States

Sponsor:

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

- 1 **Generic Name:** adalimumab
Trade Name: HUMIRA
Marketing Approval Date: 09/23/2014
Approved Labeled Indication: Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.
Exclusivity End Date: 09/23/2021
Exclusivity Protected Indication* : Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.



Humira continued

Generic Name: adalimumab
Trade Name: Humira
Date Designated: 05/11/2011
Orphan Designation: Treatment of pediatric patients with ulcerative colitis
Orphan Designation Status: Designated/Approved

Sponsor: AbbVie, Inc.
1 North Waukegan Rd
Dept PA72; Bldg AP30-4
North Chicago, Illinois 60064
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 **Generic Name:** adalimumab
Trade Name: Humira
Marketing Approval Date: 02/24/2021
Approved Labeled Indication: treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. Limitations of Use: The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers.
Exclusivity End Date: 02/24/2028
Exclusivity Protected Indication* : treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. Limitations of Use: The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers.

Generic Name: adalimumab
Trade Name: Humira
Date Designated: 05/13/2014
Orphan Designation: Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis
Orphan Designation Status: Designated/Approved

Sponsor: AbbVie, Inc.
1 North Waukegan Road
North Chicago, Illinois 60064
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 **Generic Name:** adalimumab
Trade Name: Humira
Marketing Approval Date: 06/30/2016
Approved Labeled Indication: Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients
Exclusivity End Date: 06/30/2023
Exclusivity Protected Indication* : Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients

2 **Generic Name:** adalimumab
Trade Name: Humira
Marketing Approval Date: 09/28/2018
Approved Labeled Indication: Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older
Exclusivity End Date: 09/28/2025
Exclusivity Protected Indication* : Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older



Humira continued

Generic Name: adalimumab
Trade Name: HUMIRA
Date Designated: 05/13/2015
Orphan Designation: Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)
Orphan Designation Status: Designated/Approved
Sponsor: AbbVie, Inc.
1 North Waukegan Road
North Chicago, Illinois 60064
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1	Generic Name: adalimumab Trade Name: HUMIRA Marketing Approval Date: 09/09/2015 Approved Labeled Indication: Treatment of moderate to severe hidradenitis suppurativa Exclusivity End Date: 09/09/2022 Exclusivity Protected Indication* : Treatment of moderate to severe hidradenitis suppurativa
2	Generic Name: adalimumab Trade Name: HUMIRA Marketing Approval Date: 10/16/2018 Approved Labeled Indication: Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. Exclusivity End Date: 10/16/2025 Exclusivity Protected Indication* : Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older



Rinvoq

Generic Name: upadacitinib
Trade Name: Rinvoq
Date Designated: 09/18/2015
Orphan Designation: Treatment of pediatric (aged 0 through 16 years) juvenile idiopathic arthritis (JIA) ILAR categories excluding systemic JIA
Orphan Designation Status: Designated/Approved
AbbVie, Inc.
1 North Waukegan Road
North Chicago, Illinois 60064
Sponsor: United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 **Generic Name:** upadacitinib
Trade Name: Rinvoq
Marketing Approval Date: 04/26/2024
Approved Labeled Indication: treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers, and for the treatment of pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers
Exclusivity End Date: 04/26/2031
Exclusivity Protected Indication* : treatment of pediatric patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers, and for the treatment of pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers

Generic Name: upadacitinib
Trade Name: Rinvoq
Date Designated: 09/20/2024
Orphan Designation: treatment of giant cell arteritis
Orphan Designation Status: Designated/Approved
AbbVie Inc.
1 North Waukegan Road
North Chicago, Illinois 60064
Sponsor: United States


The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 **Generic Name:** upadacitinib
Trade Name: Rinvoq
Marketing Approval Date: 04/28/2025
Approved Labeled Indication: treatment of adults with giant cell arteritis
Exclusivity End Date: TBD



Oregon Prescription Drug
Affordability Board



Oregon Prescription Drug Affordability board meeting


Survey results

Cortnee Whitlock, senior policy analyst

June 18, 2025


Drug by the number of total survey responses to the patient out-of-pocket cost range

263 surveys submitted. 258 surveys used for data analysis. Five surveys were removed due to lack of usable information.




Drug by the number of survey responses to the patient out-of-pocket cost range

Number of surveys reported for out-of-pocket cost ranges based on drug under review. Cost range not reported have been removed.




Drug by Insurance type and coverage under insurance




Rx covered by insurance type by Drug and Insurance


Insurance ● Medicaid ● Medicare ● Private health insurance



Rx covered under insurance and Rx not covered under insurance based on No. of responses by Drug



Not on patient program and On patient program by Drug





Oregon Prescription Drug
Affordability Board

Data Dashboard Web Links

Agenda item: Board review and possible vote for updated data subset list of prescription drugs and insulin products pursuant to OAR 925-200-0010

Click on the [Prescription Drug Affordability Board data web page](#) to access the data dashboard. Here are direct links to the dashboards:

- [Oregon PDAB Subset List Dashboard](#)
- [Oregon PDAB Data Dashboard](#)

Dashboard location on the PDAB website:

<https://dfr.oregon.gov/pdab/Pages/data.aspx>